三阴性乳腺癌免疫治疗耐药机制的研究进展

doi:10.11904/j.issn.1002-3070.2023.05.011

摘要/Abstract

摘要： 目的三阴性乳腺癌(Triple-negative breast cancer,TNBC)由于具有较高肿瘤突变负荷(TMB)和肿瘤浸润淋巴细胞,可受益于免疫治疗。尽管免疫治疗作为TNBC的重要治疗策略已取得突破,但最近的一些临床数据表明,很大一部分患者对免疫治疗表现出耐药,或对治疗有效果的患者出现进一步复发或进展。这些预后不良的主要原因是其复杂的内在或外在免疫逃逸机制,可能是由抗原呈递异常、免疫抑制性肿瘤微环境、与其他免疫检查点相互作用以及肿瘤细胞信号传导的异常激活引起的。然而目前对于TNBC免疫治疗耐药机制的研究尚不完善。本文将对免疫治疗所面临的挑战及TNBC对免疫治疗产生耐药性的潜在机制进行综述。

关键词: 三阴性乳腺癌, 免疫治疗, 免疫耐药

Abstract: Triple-negative breast cancer (TNBC) can benefit from immunotherapy because of its higher tumor mutational burden (TMB) and tumor-infiltrating lymphocytes. Although immunotherapy has made breakthroughs as an important treatment strategy for TNBC, recent clinical data suggest that a proportion of patients exhibit resistance to immunotherapy, or those who are effective in treatment experience further recurrence or progression. The main reason for these poor prognosis is complex internal or external immune escape mechanisms, which may be caused by abnormal antigen presentation, immunosuppressive tumor microenvironment, interactions with other immune checkpoints, and abnormal activation of tumor cell signaling. However, the research on the resistance mechanism of TNBC immunotherapy is still incomplete. This article will provide a review of the challenges faced by immunotherapy and the potential mechanisms of TNBC develops resistance to immunotherapy.

Key words: Triple negative breast cancer, Immunotherapy, Immune resistance

中图分类号:

R737.9

初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.

CHU Sitong, XU Qingyong. Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer[J]. Journal of Practical Oncology, 2023, 37(5): 449-453.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.05.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I5/449

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Andrews LP,Yano H,Vignali DA.Inhibitory receptors and ligands beyond PD-1,PD-L1 and CTLA-4:Breakthroughs or backups[J].Nat Immunol,2019,20(11):1425-1434.
3 Garrido MA,Rodriguez T,Zinchenko S,et al.HLA class I alterations in breast car-cinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15[J].Immunogenetics,2018;70(10):647-659.
4 Lee JV,Housley F,Yau C,et al.Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer[J].Nat Commun,2022,13(1):3671.
5 Nomura T,Huang WC,Zhau HE,et al.β2-Microglobulin-mediated signaling as a target for cancer therapy[J].Anticancer Agents Med Chem,2014,14(3):343-352.
6 Song X,Zhou Z,Li H,et al.Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers[J].Cancer Discov,2020,10(12):1872-1893.
7 Huang Y,Zhang HL,Li ZL,et al.FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer[J].Nat Commun,2021,12(1):2672.
8 Li XJ,Du H,Zhan SH,et al.The interaction between the soluble programmed death ligand-1(sPD-L1)and PD-1(+)regulator B cells mediates immunosuppression in triple-negative breast cancer[J].Front Immunol,2022,13:830606.
9 Castagnoli L,Cancila V,Cordoba-Romero SL,et al.WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer[J].Oncogene,2019,38(21):4047-4060.
10 Franklin DA,Sharick JT,Ericsson-Gonzalez PI,et al.MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC[J].JCI Insight,2020,5(15):e134290.
11 Franklin DA,James JL,Axelrod ML,et al.MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression[J].Cancer Drug Resist,2020,3(3):603-612.
12 Peng WY,Chen JQ,Liu CW,et al.Loss of PTEN promotes resistance to T cell-mediated immunotherapy[J].Cancer Discov,2016,6(2):202-216.
13 Wu BB,Song M,Dong Q,et al.UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer[J].Research Paper,2022,12(11):5086-5102.
14 Zhang M,Wang N,Song P,et al.LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1[J].Cell Proliferation,2020,53(9):12855.
15 Sami E,Paul BT,Koziol JA,et al.The immunosuppressive microenvironment in BRCA1-IRIS-Overexpressing TNBC tumors is induced by bidirectional interaction with tumor-associated macrophages[J].Cancer Res,2020,80(5):1102-1117.
16 Roux C,Jafari SM,Shinde R,et al.Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1[J].Proc Natl Acad Sci U S A,2019,116(10):4326-4335.
17 Ji P,Gong Y,Jin ML,et al.In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer[J].Sci Adv,2022,8(26):eabl8247.
18 Liu L,Cheng XF,Yang H,et al.BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion[J].Mol Cancer,2022,21(1):59.
19 Knutson KL,Disis ML.Tumor antigen-specific T helper cells in cancer immunity and immunotherapy[J].Cancer Immunol Immunother,2005,54(8):721-728.
20 Guery L,Hugues S.Th17 cell plasticity and functions in cancer immunity[J].Biomed Res Int,2015,2015:314620.
21 Han GC,Yang GL,Hao DP,et al.9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy[J].Nat Commun,2021,12(1):5606.
22 Ciriello G,Gatza ML,Beck AH,et al.Comprehensive molecular portraits of invasive lobular breast cancer[J].Cell,2015,163(2):506-519.
23 Yu B,Luo,F,Sun B,et al.KAT6A Acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment,metastasis,and immunotherapy in Triple-Negative breast cancer[J].Adv Sci(Weinh),2022,9(3):2105793.
24 Patel SA,Meyer JR,Greco SJ,et al.Mesenchymal stem cells protect breast cancer cells through regulatory T cells:role of mesenchymal stem cell-derived TGF-beta[J].J Immunol,2010,184(10):5885-5894.
25 Costa A,Kieffer Y,Scholer-Dahirel A,et al.Fibroblast heterogeneity and immunosuppressive environment in human breast cancer[J].Cancer Cell,2018,33(3):463-479.
26 Lu HQ,Samanta D,Xiang LS,et al.Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype[J].Proc Natl Acad Sci U S A,2015,112(33):4600-4609.
27 Bai XP,Ni J,Beretov J,et al.Cancer stem cell in breast cancer therapeutic resistance[J].Cancer Treat Rev,2018,69:152-163.
28 Bagati A,Kumar S,Jiang P,et al.Integrin αvβ6-TGFβ-SOX4 pathway drives immune evasion in triple-negative breast cancer[J].Cancer Cell,2021,39(1):54-67.
29 Cheng SW,Chen PC,Lin MH,et al.GBP5 repression suppresses the metastatic potential and PD-L1 expression in triple-negative breast cancer[J].Biomedicines,2021,9(4):371.
30 Li W,Tanikawa T,Kryczek I,et al.Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer[J].Cell Metab,2018,28(1):87-103.
31 Lim S,Li CW,Xia WY,et al.EGFR signaling enhances aerobic glycolysis in triple negative breast cancer cells to promote tumor growth and immune escape[J].Cancer Res,2016,76(5):1284-1296.
32 Chaturvedi P,Gilkes DM,Takano N,et al.Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment[J].Proc Natl Acad Sci U S A,2014,111(20):2120-2129.
33 Ma SJ,Zhao Y,Lee WC,et al.Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy[J].Nat Commun,2022,13(1):4118.

[1]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[2]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[3]	李娟, 刘家仁. 胃癌免疫治疗的研究现状及进展[J]. 实用肿瘤学杂志, 2023, 37(4): 372-376.
[4]	李路桥, 邹征云. 恶性黑色素瘤免疫治疗超进展研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 144-148.
[5]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[6]	杨菊, 刘芹, 刘宝瑞, 魏嘉. 胃癌相关癌睾抗原筛选与免疫浸润分析[J]. 实用肿瘤学杂志, 2022, 36(6): 495-501.
[7]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[8]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[9]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[10]	程思远, 韩子翰, 郭晓欢, 沈琳, 彭智. 肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 520-525.
[11]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[12]	童曼琳, 尚茹茹, 刘晓红. PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 278-282.
[13]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[14]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[15]	史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.